SynOx Therapeutics Ireland United States of America United Kingdom

SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibodyProvides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation Funding is additional to recent $75m Series B financingView original content:https://www.prnewswire.co.uk/news-releases/synox-therapeutics-secures-up-to-35m-debt-financing-with-hercules-capital-to-progress-development-and-commercialisation-of-emactuzumab-302130421.html